Manulife (Manufacturers Life Insurance)’s Cidara Therapeutics CDTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-11,409
| Closed | -$2.52M | – | 2829 |
|
|
2025
Q4 | $2.52M | Buy |
11,409
+2,872
| +34% | +$464K | ﹤0.01% | 1427 |
|
|
2025
Q3 | $818K | Buy |
+8,537
| New | +$545K | ﹤0.01% | 1969 |
|
|
2020
Q4 | – | Sell |
-1,141
| Closed | -$65K | – | 2994 |
|
|
2020
Q3 | $65K | Hold |
1,141
| – | – | ﹤0.01% | 2875 |
|
|
2020
Q2 | $86K | Buy |
+1,141
| New | +$73.9K | ﹤0.01% | 2791 |
|
|
2018
Q3 | – | Hold |
0
| – | – | – | 3061 |
|
|
2018
Q2 | – | Hold |
0
| – | – | – | 4298 |
|
|
2018
Q1 | – | Sell |
-13
| Closed | -$1.78K | – | 4327 |
|
|
2017
Q4 | $2K | Hold |
13
| – | – | ﹤0.01% | 4215 |
|
|
2017
Q3 | $2K | Sell |
13
-13
| -50% | -$1.85K | ﹤0.01% | 4102 |
|
|
2017
Q2 | $4K | Sell |
26
-596
| -96% | -$82.4K | ﹤0.01% | 3974 |
|
|
2017
Q1 | $97K | Buy |
622
+54
| +10% | +$9.48K | ﹤0.01% | 3199 |
|
|
2016
Q4 | $118K | Buy |
568
+412
| +264% | +$85.6K | ﹤0.01% | 3152 |
|
|
2016
Q3 | $36K | Buy |
156
+135
| +643% | +$31.2K | ﹤0.01% | 3455 |
|
|
2016
Q2 | $4K | Sell |
21
-43
| -67% | -$10.4K | ﹤0.01% | 3851 |
|
|
2016
Q1 | $14K | Buy |
64
+60
| +1,500% | +$13.8K | ﹤0.01% | 3567 |
|
|
2015
Q4 | $1K | Hold |
4
| – | – | ﹤0.01% | 3865 |
|
|
2015
Q3 | $1K | Hold |
4
| – | – | ﹤0.01% | 3905 |
|
|
2015
Q2 | $1K | Buy |
+4
| New | +$1.23K | ﹤0.01% | 3892 |
|
Manulife (Manufacturers Life Insurance)'s CDTX Position: Q1 2026 in Review
Manulife (Manufacturers Life Insurance) sold out of Cidara Therapeutics (CDTX) in Q1 2026, closing a stake of 11,409 shares — an estimated $2.52M sold.
Manulife (Manufacturers Life Insurance) first reported a position in CDTX in Q2 2015 and held it in 15 quarters. The position peaked at $2.52M in Q4 2025. 0 funds tracked by Wall St. Rank hold CDTX as of Q1 2026.
- Manulife (Manufacturers Life Insurance) reported no remaining Cidara Therapeutics position as of Q1 2026 after selling out during the quarter.
- Manulife (Manufacturers Life Insurance) sold 11,409 Cidara Therapeutics shares in Q1 2026, an estimated $2.52M.
- Manulife (Manufacturers Life Insurance) first reported a position in Cidara Therapeutics in Q2 2015 and held it in 15 quarters.
- Manulife (Manufacturers Life Insurance)'s Cidara Therapeutics position peaked at $2.52M in Q4 2025.
- 0 funds tracked by Wall St. Rank held Cidara Therapeutics as of Q1 2026.
Based on Manulife (Manufacturers Life Insurance)'s 13F filing for Q1 2026, filed 15 May 2026.